BridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Purchased by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd increased its position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 95.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 25,980 shares of the company’s stock after purchasing an additional 12,701 shares during the period. Y Intercept Hong Kong Ltd’s holdings in BridgeBio Pharma were worth $713,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the company. Advisors Asset Management Inc. increased its holdings in shares of BridgeBio Pharma by 56.1% during the 3rd quarter. Advisors Asset Management Inc. now owns 4,576 shares of the company’s stock worth $117,000 after buying an additional 1,645 shares during the last quarter. Allspring Global Investments Holdings LLC grew its position in BridgeBio Pharma by 17.7% in the third quarter. Allspring Global Investments Holdings LLC now owns 5,322 shares of the company’s stock worth $135,000 after acquiring an additional 801 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in BridgeBio Pharma by 21.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,801 shares of the company’s stock worth $170,000 after acquiring an additional 1,214 shares during the last quarter. Avanza Fonder AB purchased a new stake in BridgeBio Pharma in the fourth quarter valued at $181,000. Finally, First Bank & Trust purchased a new stake in BridgeBio Pharma in the fourth quarter valued at $205,000. 99.85% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts recently issued reports on BBIO shares. Evercore ISI raised their price objective on BridgeBio Pharma from $45.00 to $50.00 and gave the stock an “outperform” rating in a research report on Monday, December 23rd. Cantor Fitzgerald reiterated an “overweight” rating and set a $95.00 price target on shares of BridgeBio Pharma in a research report on Friday, February 21st. Scotiabank boosted their price target on shares of BridgeBio Pharma from $49.00 to $52.00 and gave the company a “sector outperform” rating in a research note on Friday, February 21st. Citigroup increased their price objective on shares of BridgeBio Pharma from $45.00 to $49.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. Finally, Bank of America boosted their target price on BridgeBio Pharma from $42.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, November 25th. One investment analyst has rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $51.67.

Insider Activity at BridgeBio Pharma

In other news, CFO Brian C. Stephenson sold 8,500 shares of the business’s stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $33.19, for a total transaction of $282,115.00. Following the completion of the sale, the chief financial officer now owns 102,464 shares in the company, valued at approximately $3,400,780.16. The trade was a 7.66 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Neil Kumar sold 326,932 shares of the stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $36.29, for a total transaction of $11,864,362.28. Following the completion of the transaction, the chief executive officer now directly owns 5,371,515 shares in the company, valued at $194,932,279.35. This trade represents a 5.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 3,579,739 shares of company stock valued at $125,411,901 over the last quarter. 24.66% of the stock is owned by insiders.

BridgeBio Pharma Stock Performance

BBIO stock opened at $34.90 on Friday. The company’s 50 day moving average price is $32.68 and its 200 day moving average price is $28.29. The firm has a market capitalization of $6.64 billion, a price-to-earnings ratio of -12.25 and a beta of 1.07. BridgeBio Pharma, Inc. has a fifty-two week low of $21.62 and a fifty-two week high of $39.47.

BridgeBio Pharma (NASDAQ:BBIO) last announced its quarterly earnings data on Thursday, February 20th. The company reported ($1.31) EPS for the quarter, missing analysts’ consensus estimates of ($1.09) by ($0.22). The business had revenue of $5.88 million for the quarter, compared to the consensus estimate of $4.04 million. Equities analysts forecast that BridgeBio Pharma, Inc. will post -3.67 EPS for the current fiscal year.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.